- Home
- ED vs LIVN Comparison
ED vs LIVN Comparison
Compare ED & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ED
- LIVN
- Stock Information
- Founded
- ED 1884
- LIVN 1987
- Country
- ED United States
- LIVN United Kingdom
- Employees
- ED 14592
- LIVN N/A
- Industry
- ED Power Generation
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ED Utilities
- LIVN Health Care
- Exchange
- ED Nasdaq
- LIVN Nasdaq
- Market Cap
- ED 31.0B
- LIVN 2.8B
- IPO Year
- ED N/A
- LIVN 1993
- Fundamental
- Price
- ED $89.41
- LIVN $47.63
- Analyst Decision
- ED Hold
- LIVN Buy
- Analyst Count
- ED 12
- LIVN 7
- Target Price
- ED $98.17
- LIVN $67.14
- AVG Volume (30 Days)
- ED 2.1M
- LIVN 513.2K
- Earning Date
- ED 02-13-2025
- LIVN 02-19-2025
- Dividend Yield
- ED 3.72%
- LIVN N/A
- EPS Growth
- ED N/A
- LIVN 759.09
- EPS
- ED 5.31
- LIVN 0.43
- Revenue
- ED $15,031,000,000.00
- LIVN $1,241,739,000.00
- Revenue This Year
- ED $7.23
- LIVN $10.10
- Revenue Next Year
- ED $3.78
- LIVN $5.43
- P/E Ratio
- ED $16.83
- LIVN $110.48
- Revenue Growth
- ED N/A
- LIVN 11.04
- 52 Week Low
- ED $85.85
- LIVN $43.15
- 52 Week High
- ED $107.75
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- ED 39.64
- LIVN 46.19
- Support Level
- ED $87.28
- LIVN $46.02
- Resistance Level
- ED $89.11
- LIVN $48.13
- Average True Range (ATR)
- ED 1.18
- LIVN 1.12
- MACD
- ED 0.31
- LIVN 0.19
- Stochastic Oscillator
- ED 74.74
- LIVN 78.00
About ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.